Health System Targeting FibriCheck already penetrates the clinical market through a broad network of practices and a wide user base across multiple countries, supported by CE IIa, MHRA, FDA and TGA approvals, making it well-positioned to expand adoption with hospitals, health systems, and payers and to articulate ROI through faster diagnosis and improved outcomes.

Wearable Partnerships The device-agnostic software and recent Samsung Galaxy watch integration demonstrate a path to broaden patient access by expanding to additional wearables and consumer devices, enabling broader data capture and remote monitoring opportunities.

Data Registry Monetization The FibriCheck Data Registry creates real-world evidence assets that can support research, regulatory submissions, and payer conversations; this offers a potential revenue or co-development stream with pharma, research groups, and healthcare organizations while driving product validation.

Remote Monitoring Value The platform supports symptom logging, patient lifecycle coverage from detection to management, and easy physician sharing, positioning it as a core RPM solution for NHS/UK pilots and other health systems seeking cost savings and improved arrhythmia care.

Market Validation Awards and recognitions alongside ongoing clinical studies reinforce credibility and momentum, helping to unlock larger enterprise deals and multi-site deployments.